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We recently reported that CXCL14 binds to CXCR4 with high afﬁnity and inhibits CXCL12-mediated
chemotaxis. Here we found that the C-terminal 51–77 amino acid residues of CXCL14 are responsible
for CXCR4 binding. A disulﬁde dimer peptide of CXCL14(51–77) bound to CXCR4 with comparable
afﬁnity to full length CXCL14, and exhibited CXCL12 inhibitor activity. CXCR4 was efﬁciently inter-
nalized upon binding of dimeric CXCL14(51–77), thereby being reduced on the cell surface. Substi-
tution of 5 amino acid residues in combination with the use of an oxime linker for dimerization
increased the solubility and chemical stability of the dimeric CXCL14(51–77).
Structured summary of protein interactions:
CXCL14 physically interacts with CXCL14 by anti tag coimmunoprecipitation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
CXCL12 and its receptor CXCR4 have critical functions in the
migration of various types of tissue stem cells and immune cells
[1]. Besides, CXCL12–CXCR4 signaling pathway is closely related
to the malignant growth and metastasis of more than 20 different
human neoplasms, including lung, breast, prostate and ovarian
cancers [2]. Elevated levels of CXCL12 and its receptors are associ-
ated with poor prognosis in many of these cases [2,3]. These facts
highlight the importance of accurate understanding of CXCL12–
CXCR4 axis regulation.
Despite of relatively low sequence similarity among the chemo-
kine family members, they display a conserved tertiary structure
consisting of a ﬂexible N-terminal region, a three antiparallel
b-sheet strand and a C-terminal a-helix [4]. It has been shown that
the N-terminal region plays a crucial role in the ligand–receptor
interaction [5–7]. In the case of CXCL12, interaction between its
N-terminal region and transmembrane helices of CXCR4 is essen-
tial for conformational changes leading to signal transduction
[6,8]. Very recently, we showed that CXCL14 speciﬁcally binds toCXCR4 with high afﬁnity, and inhibits the CXCL12-mediated
chemotaxis of leukemia-derived cells and hematopoietic progeni-
tors [9]. Intriguingly, CXCL14 is devoid of the N-terminal region
corresponding to the receptor-binding domain of CXCL12 [10],
suggesting that CXCL14 interacts with CXCR4 in a distinct fashion.
In this study, we ﬁrst determined a critical domain of CXCL14
that is required for its inhibitory action on the CXCL12–CXCR4
signaling. Based on it, we newly found that dimeric peptides of
the C-terminal region of CXCL14 act as novel CXCL12 inhibitors.2. Materials and methods
2.1. Cell culture
Human monocytic leukemia-derived cell line THP-1 (JCRB0112)
was obtained from the Human Science Research Resource Bank
(Osaka, Japan). THP-1 cell line was maintained at 37 C in
RPMI-1640 medium (Sigma, St. Louis, MO) containing 10% FCS
(Invitrogen, Carlsbad, CA), 0.5% penicillin–streptomycin (Sigma),
and 50 lM b-mercaptoethanol (Sigma).
2.2. Binding assays
Human CXCL14 (Peprotech, Rocky Hill, NJ) and human CXCL12
(Peprotech) were labeled with 125I by Bolton–Hunter reagent (Per-
Fig. 1. Biological activities of chemically synthesized peptides derived from CXCL14
and CXCL12. (A) Schematic representation of the synthetic peptides used in this
study. (B) Competitive inhibition of the CXCL14 binding by CXCL14-derived
peptides. THP-1CXCR4 cells were incubated with 10 nM 125I-CXCL14 in the presence
or absence of 100 nM indicated synthetic peptide, and cell-associated radioactivity
was measured (n = 6). Relative binding of 125I-CXCL14 to no competitor control was
shown. (C) Inhibitory activity of ssdmCXCL14-C in the CXCL12-mediated chemo-
taxis. Migratory responses of THP-1 cells to 10 nM CXCL12 in the presence or
absence of 100 nM indicated peptide were examined (n = 3). Data are shown as
chemotactic index: i.e. migrated cell number to CXCL12 divided by migrated cell
number to the medium alone. In B and C, ⁄P < 0.05; ⁄⁄P < 0.01 compared to the value
in the absence of peptide (B) or CXCL12 (C).
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Japan) in an Iodogen (Pierce, Rockford, IL)-coated tube,
respectively. Binding assays were carried out as previously de-
scribed [9,11].
2.3. Chemotaxis assay
THP-1 cells were washed and resuspended at 106 cells/ml in
RPMI-1640 containing 0.1% fatty acid-free BSA (Sigma) and
20 mM HEPES (pH 7.5) (Invitrogen). The wells of a 24-well culture
plate were ﬁlled with 550 ll of 10 nM CXCL12. Chemotaxicell ﬁl-
ters (5 lm pore size; Kurabo, Osaka, Japan) were placed in each
well and test cells in the presence of 100 nM CXCL14 or its deriv-
ative peptides (200 ll) were added to the upper chamber. The plate
was then incubated for 2 h at 37 C. The numbers of cells that pen-
etrated the wells were also counted and added to the cell number
on the bottom surface of the chamber. Chemotactic index was de-
ﬁned as total number of migrated cells to the CXCL12 containing
medium divided by migrated cell number in the control medium.
2.4. Chemical synthesis of CXCL14-derived peptides
CXCL14 peptide (77 amino acid residues) was chemically syn-
thesized as previously described [12], and used as full length
CXCL14 in this study. CXCL14(1–50)–CXCL12(51–72) chimera and
CXCL(D29–49) were also synthesized by the procedure essentially
similar to that used for the full length CXCL14. For the preparation
of C-terminal 51–77 amino acid residues of CXCL14 (referred to as
CXCL14-C hereafter), protected peptide resin corresponding to
CXCL14(51–77) wasmanually constructed using standard 9-ﬂuore-
nylmethyloxycarbonyl solid-phase peptide synthesis (loading:
0.24 mmol/g). The resulting completed resin (25.0 mg) was treated
with triﬂuoroacetic acid (TFA)–thioanisole–m-cresol–H2O–1,2 eth-
anediol [80:5:5:5:5, (v/v)] at room temperature for 1.5 h. After the
resin was ﬁltered off, cooled diethylether was added to the ﬁltrate,
and precipitate was collected by centrifugation. The precipitate was
washedwith diethylether and puriﬁed by preparative HPLC. To pro-
duce a disulﬁde dimer peptide of CXCL14-C (designated
ssdmCXCL14-C), N-terminal cysteinyl residue was coupled on the
above described resin to construct an intermolecular disulﬁde
bond. Treatment of the resin corresponding to CXCL14(50–77) with
the TFA reagent cocktail was followed by incubation in 0.1 M
sodium phosphate buffer (pH 7.7) at a concentration of 1.0 mM at
37 C for 12 h and subsequent HPLC puriﬁcation gave the disulﬁde
dimer peptide (ssdmCXCL14-C). For the synthesis of oxime dimer
peptides, aminooxyacetic acid was assembled on the resin corre-
sponding to CXCL14(51–77). Deprotection with the TFA-based
reagent afforded the N-terminally aminooxy-modiﬁed peptide,
which was then dimerized with the aid of bis-aldehyde linker via
oxime formation. Circular dichroism (CD) spectrum of the synthe-
sized peptide was measured according to the published method
[13]. Far-UV CD spectra were recorded from 185 to 260 nm at
25 C using a J-600 spectropolarimeter (Jasco Corporation, Tokyo,
Japan). The peptide solutions of 50 mg/ml in 10 mM sodium phos-
phate buffer (pH 7.0) were subjected to CDmeasurement in a 2 mm
quartz cuvette.
2.5. Fluorescent activated cell sorting (FACS)
THP-1CXCR4 cells [9] were pre-treated with CXCL12, CXCL14 or
CXCL14-derived peptides at 37 C for 15–60 min. They were imme-
diately chilled, stained with allophycocyanin-conjugated mouse
anti-human CXCR4 (clone 12G5; BioLegend, San Diego, CA) or
APC-conjugated mouse isotype control (clone MOPC-173; Bioleg-
end), and subjected to the analysis on a FACSCanto (BD Biosciences,
San Jose, CA). Cycloheximide (10 lg/ml; Sigma) was added to themedium during the chemokine treatment to prevent de novo pro-
tein synthesis.
2.6. Statistical analyses
All statistical analyses were performed using ANOVA repeated
measures analysis using functions on Microsoft Excel. A P-value
of <0.05 was considered signiﬁcant for the unpaired Student’s t-
test. Each value in ﬁgures represents the mean ± standard errors.
⁄P < 0.05, ⁄⁄P < 0.01, otherwise not signiﬁcant to the reference
sample.
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3.1. C-terminal region of CXCL14 is involved in the CXCL14–CXCR4
interaction
To determine which region of CXCL14 is responsible for the
interaction with CXCR4, we measured the binding competition
activity of various CXCL14-derived peptides (Fig. 1A) by employing
the high afﬁnity binding assay of 125I-labeled CXCL14 with the
CXCR4 transfectant of THP-1 (THP-1CXCR4) cells [9]. A deletion mu-
tant of 29–49 amino acid residues in the middle region of CXCL14
[CXCL14(D29–49)] competed with high afﬁnity binding of 125I-
CXCL14 as similar as the full length CXCL14 (Fig. 1B). On the other
hand, a CXCL14–CXCL12 chimeric peptide [CXCL14(1–50)–
CXCL12(51–72)] did not show such competitive activity. These re-
sults indicated that C-terminal 51–77 amino acid residues of
CXCL14 are required for the CXCR4 binding. However, monomeric
C-terminal peptide of CXCL14 (CXCL14-C) weakly competed with
the 125I-CXCL14 binding. Thus, the C-terminal 51–77 region is
essential, but not sufﬁcient for the CXCL14–CXCR4 interaction.
Our recent study revealed that a dimeric form of CXCL14 is
associated with CXCR4 in THP-1 cells [9]. Thus we generated a
dimer peptide of CXCL14-C (ssdmCXCL14-C) that is coupled with
disulphide bond at N-terminal cystein (Fig. 1A). Interestingly,
ssdmCXCL14-C displayed a stronger competitive binding activity
than its monomer form and it was similar extent with that of the
full length CXCL14 (Fig. 1B). We next determined whether
ssdmCXCL14-C inhibits the chemotactic activity of CXCL12.Fig. 2. Molecular basis of the inhibitory action of CXCL14 and ssdmCXCL14-C to the C
dmCXCL14-C. THP-1CXCR4 cells were incubated with 10 nM 125I-CXCL14 in the presence o
measured (n = 4). Relative binding of 125I-CXCL14 to no competitor control was shown. (B
1 nM 125I-CXCL12 in the presence of various concentrations of unlabeled CXCL12 or CXC
internalization by CXCL14 and dmCXCL14-C. THP-1CXCR4 cells were treated with 10 nM CX
surface was determined by FACS (n = 6–9). In B and C, ⁄P < 0.05; ⁄⁄P < 0.01 compared to t
CXCL12-stimulated ERK phosphorylation by CXCL14. THP-1CXCR4 cells were cultured in th
15 min with or without 10 or 100 nM CXCL14. Equal amount of total protein was loadePresence of ssdmCXCL14-C in the upper chamber blocked the
CXCL12-mediated migration of THP-1 cells to the lower chamber,
whereas addition of monomeric CXCL14-C was not effective
(Fig. 1C). The inhibitory activity of ssdmCXCL14-C was comparable
to that of the full length CXCL14. Importantly, ssdmCXCL14-C itself
did not possess any chemotactic activity in THP-1 cells (data not
shown). These results suggested that ssdmCXCL14-C is an efﬁcient
CXCL12 inhibitor.
Previous structural study demonstrated that CXCL14 exists as a
monomer in solution [10]. To determine whether CXCL14 could
form a dimer, we carried out immunoprecipitation assays with
using HA- and FLAG-tagged CXCL14. CXCL14-HA was co-immuno-
precipitated with CXCL14-FLAG, but not with CXCL12-FLAG when
they co-expressed in COS7 cells (Fig. S1), indicating that CXCL14
exists as a dimeric form in the cells.3.2. CXCL14 and ssdmCXCL14-C induce endocytosis of CXCR4
We compared the binding afﬁnity of ssdmCXCL14-C or mono-
meric CXCL14-C with that of the full length CXCL14. Based on com-
petitive binding curves on THP-1CXCR4 cells, IC50 of ssdmCXCL14-C
was 14.9 nM, which was comparable to that of CXCL14 (11.5 nM)
(Fig. 2A). Inability of speciﬁc competition in high concentration
ranges (100–1000 nM) in the case of ssdmCXCL14-C could be due
to the lack of heparin binding capacity. In contrast, IC50 value of
monomeric CXCL14-C was 51 nM (Fig. 2A). Thus, dimerization of
CXCL14-C enhanced its binding afﬁnity to CXCR4.XCL12–CXCR4 signaling axis. (A) Competitive inhibition of the CXCL14 binding by
f various concentrations of indicated peptides, and cell-associated radioactivity was
) Cross inhibition of the CXCL12 binding by CXCL14. THP-1 cells were incubated with
L14, and cell-associated radioactivity was measured (n = 3). (C) Induction of CXCR4
CL12, 100 nM CXCL14, or 100 nM ssdmCXCL14-C. Expression level of CXCR4 on cell
he value without competitor (B), or the value of untreated cells (C). (D) Inhibition of
e absence of FCS for 1 h and treated with PBS (control) or 1 nM CXCL12 at 37 C for
d for Western blot analysis.
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CXCR4, we performed competitive binding assays of 125I-labeld
CXCL12 with using CXCL12 or CXCL14 as a competitor. In THP-1
cells, binding of 1 nM 125I-labeled CXCL12 was completely blocked
by 100 nM of unlabeled CXCL12, but not of 100 nM CXCL14
(Fig. 2B). An extremely high concentration (IC50 = 1000 nM) of
CXCL14 was required for the complete inhibition of 125I-CXCL12
binding (Fig. 2B), and it was 10 times higher than the effective con-
centration required for the competitive inhibition of 125I-CXCL14
binding (Fig. 2A). These results implicate that the high afﬁnity
binding sites of CXCL14 and CXCL12 on CXCR4 are different.
CXCR4 and other chemokine receptors are known to be inter-
nalized after chemokine stimulation [14]. Therefore, we next
investigated the cell surface expression levels of CXCR4 before
and after stimulation with CXCL12, CXCL14, or ssdmCXCL14-C.
Based on FACS analyses with THP-1CXCR4 cells, CXCL14 and
ssdmCXCL14-C induced the internalization of CXCR4 as similar as
CXCL12 (Fig. 2C). Stimulation of CXCL12 induced rapid phosphory-
lation of ERK, which was inhibited by 100 nM CXCL14 (Fig. 2D). At
that time point (15 min), CXCR4 was internalized by CXCL14 treat-
ment (Fig. 2C). These results demonstrated that CXCL14 and
ssdmCXCL14-C decreases the availability of CXCR4 on cell surface,
thereby interfering the CXCL12-mediated signal transduction.Fig. 3. (A) CD spectra of ssdmCXCL14-C and its derivative peptides. (B) Competitive in
were incubated with 10 nM 125I-CXCL14 in the presence or absence of 100 nM indicated
125I-CXCL14 to no competitor control was shown. (C) Effective competition of the CXCL
I-CXCL14 in the presence of various concentrations of indicated peptide, and cell-asso
chemotaxis by oxdmCXCL14-Cc/g. Migratory responses of THP-1 cells to 10 nM CXCL12
examined (n = 3). In B and D ⁄P < 0.05; ⁄⁄P < 0.01 compared to the value in the absence3.3. Generation of more stable derivatives of dmCXCL14-C
As shown above, ssdmCXCL14-C is a novel inhibitor for the
CXCL12–CXCR4 signaling axis. However, it may be unstable
in vivo since disulﬁde bond is easily reduced by endogenous thiols
such as glutathione in the body. It has been shown that modiﬁca-
tion to strengthen the a-helicity of short peptides improves their
biological activity from a structural viewpoint [15]. Introduction
of glutamic acid (E) and lysine (K) at i (amino acid residue number)
and i+4 positions was reported to enhance the a-helicity via intra-
helical salt bridge formation (Fig. S2A and B) [15]. Based on this
ﬁnding, we chemically modiﬁed ssdmCXCL14-C by pair-wise intro-
duction of E and K to generate 4 different derivatives: i.e.
ssdmCXCL14-Cb/f [ssdmCXCL14(51–77:L55E/I62E/N66K/N69E/
R73K)], ssdmCXCL14-Cc/g [ssdmCXCL14(51–77:Q56E/R60K/K63E/
A67K/V74K)], ssdmCXCL14-Cf/c [ssdmCXCL14(51–77:Q56K/K59E/
N66E/E70K/R73E/E77K)], ssdmCXCL14-Cg/d [ssdmCXCL14
(51–77:S57K/R60E/W64K/A67E)] (Fig. S2A–C). Measurement of
CD spectrum of each peptide indicated that the a-helicity of
ssdmCXCL14-Cc/g and ssdmCXCL14-Cf/c was stronger than
ssdmCXCL14-C based on the characteristic signals at 208 and
222 nm for a-helical structure (Fig. 3A). We next examined the
competitive 125I-CXCL14 binding ability of 4 modiﬁedhibition of the CXCL14 binding by various dmCXCL14-C peptides. THP-1CXCR4 cells
peptide, and cell-associated radioactivity was measured (n = 6). Relative binding of
14 binding by oxdmCXCL14-Cc/g. THP-1CXCR4 cells were incubated with 10 nM 125
ciated radioactivity was measured (n = 3). (D) Inhibition of the CXCL12-mediated
in the presence or absence of 100 nM ssdmCXCL14-C or oxdmCXCL14-Cc/g were
of competitors.
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petedwith 125I-CXCL14 binding to THP-1CXCR4 cells a little bit better
than ssdmCXCL14-C, while the other 3 peptideswere not so compe-
tent (Fig. 3B). Consistent with this result, among 4 disulﬁde dimer
derivatives, only ssdmCXCL14-Cc/g possessed the CXCL12 inhibi-
tory activity when we used mouse proB-derived BaF/3 cells
(Fig. S3).
We next introduced the oxime linker [16], which is more chem-
ically stable than the disulﬁde linkage, to generate oxdmCXCL14-
Cc/g (Fig. S2D). This artiﬁcial peptide was soluble in PBS (more
than 1 mg/ml). In contrast, an oxime dimer peptide of the parental
C-terminal fragment (CXCL14-C) displayed reduced solubility in
PBS (less than 0.1 mg/ml). Competitive binding data revealed that
oxdmCXCL14-Cc/g inhibited the 125I-CXCL14 binding to THP-1
CXCR4 with an IC50 of 4.9 nM (Fig. 3C), which was much efﬁcient
than the full length CXCL14 (11.5 nM; Fig. 2A). In contrast, IC50 va-
lue of monomeric form of CXCL14-Cc/g was 161.1 nM (Fig. 3C),
conﬁrming the importance of dimerization for the CXCL12 inhibi-
tory activity. Expectedly, the CXCL12-mediated migration of THP-
1 cells was inhibited by oxdmCXCL14-Cc/g as similar as
ssdmCXCL14-C (Fig. 3D). Taken together, we conclude that
oxdmCXCL14-Cc/g is the most promising compound as a
CXCL14-based CXCL12 inhibitor.
4. Discussion
It has been shown that some chemokines form homodimers, as
ﬁrst reported in monocyte chemoattractant protein 1 [17]. CXCL12
is also known to form dimers at high concentrations (Kd = 100–250
lM) [18]. Previous study showed that the dimeric form of CXCL12
inhibited the chemotactic response by monomeric CXCL12 [19].
Our results suggested that the C-terminal 51–77 region of CXCL14
was required but not sufﬁcient for the CXCR4 binding. However,
dimerized peptides of CXCL14-C were capable to binding CXCR4
with high afﬁnity and efﬁciently inhibited the CXCL12-mediated
chemotaxis. Dimerized CXC chemokine has two a-helices at each
C-terminal region that are aligned together in parallel [20].
Dimerized peptides of CXCL14-C may possess natural alignment
of a-helix in a dimeric form of CXCL14. Elucidation of a structural
basis of the CXCL14–CXCR4 interaction will be an important step
to better understand the action mechanism of this chemokine.
For therapeutic application of the peptide inhibitors, it is
important that they are soluble and stable in vivo, in addition to
their target speciﬁcity. From a structural point of view, enhance-
ment of a-helicity is one of the suitable ways to achieve better
performance in these aspects. We introduced the intra-helical salt
bride formation by modifying pairwise introduction of E and K
that forms ion pair when introduced i and i+4 positions.
oxdmCXCL14-Cc/g, one of the modiﬁed peptides of CXCL14-C,
displayed improved a-helicity and retained the high afﬁnity CXCR4
binding. It has two advantages over ssdmCXCL14-C. First,
oxdmCXCL14-Cc/g has a higher binding afﬁnity to CXCR4, probably
due to the enhanced a-helical conformation of CXCL14-C by reduc-
ing the energy for interacting with CXCR4. Although full-length
CXCL14 has a-helix at the C-terminal region, we found that
ssdmCXCL14-C did not have a deﬁned secondary structure accord-
ing to the CD spectrum. This unﬁxed structure may result in the
weaker interaction with CXCR4. Second, oxdmCXCL14-Cc/g
possesses higher solubility than oxdmCXCL14-C. The oxime linker
dimer of CXCL14-C exhibited a reduced solubility, suggesting
that the salt bridge formation ameliorated the hydrophobicity of
the oxime-liked peptide. Enforced salt bridge formation is an
applicable method to improve the peptide for medical use.
We recently reported that CXCL14 inhibits the CXCL12-medi-
ated cell migration of human leukemia-derived cells [9]. Thus,
CXCL14 is potentially useful for the pharmacological inhibition ofthe CXCL12–CXCR4 axis, which has recently been caught an atten-
tion because activation of CXCL12 or CXCR4 is associated with poor
prognosis in many types of cancer patients [2]. AMD3100, one of
the most speciﬁc and efﬁcient inhibitors of the CXCL12–CXCR4 axis
has been designed for disrupting CXCL12 and CXCR4 interaction
[21]. Since CXCL14 has a distinct binding site on CXCR4 from
CXCL12, CXCL14 and its derived peptides may have additive effects
to preexisting CXCL12 inhibitors. In vivo functions of oxdmCXCL14-
Cc/g are currently being investigated in this laboratory.
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